77 results about "Xanthine oxidase" patented technology

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The invention discloses a natural product composition and application thereof in reducing uric acid and blood sugar. The composition is prepared from luteolin, verbascoside and curcumin according to the weight ratio of 1: 3: 2. According to the invention, when luteolin, verbascoside and curcumin are combined according to a weight ratio of 1: 3: 2, the inhibitory activity on xanthine oxidase (XO) and alpha-glycosidase is the strongest, and the inhibitory activity is obviously superior to the inhibitory activity on xanthine oxidase (XO) and alpha-glycosidase when the luteolin, verbascoside and curcumin are independently used, so that the composition has a synergistic effect on reducing the level of uric acid and regulating blood sugar. The discovery provides a theoretical basis and a formula basis for developing novel natural-source functional products for reducing uric acid and reducing blood sugar, and has important application prospects and development values.

The present application relates to the preparation and application field of biological peptide, and more particularly to a hippocampus abdominalis peptide and its application in preparation of products for reducing uric acid and resisting gout. The amino acid sequence is shown as SEQ ID NO. 1, and the present application confirms the uric acid reducing effect through in vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on this basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a high uric acid animal model. This achievement provides a solid theoretical support for high-value development and utilization of hippocampus abdominalis, and research and development of products for reducing uric acid and resisting gout.

The invention discloses uric acid-reducing peptide goat milk powder and a preparation method thereof, and belongs to the technical field of enzymes. According to the process for preparing the uric acid lowering peptide by hydrolyzing goat milk through the compound enzyme, the total addition amount of the compound enzyme (the enzyme activity ratio of neutral protease N to neutral protease X is 1: 1) is 4000 U / g-6000 U / g, enzymolysis is conducted for 2-3 h at the temperature of 45-55 DEG C, and under the condition, the xanthine oxidase inhibition rate is 71.67 + / -1.32%-83.64 + / -0.98%. The enzymolysis goat milk containing the uric acid-reducing peptide is subjected to spray drying to prepare the uric acid-reducing peptide goat milk powder, and the storage stability of the goat milk powder is relatively good. The amino acid sequence and the source of the uric acid lowering peptide are separated and identified, the in-vitro uric acid lowering activity of the uric acid lowering peptide is verified through the solid-phase synthesized uric acid lowering peptide, and a theoretical basis and technical support are provided for development of new uric acid lowering peptide goat milk products.

This invention discloses a benzofuran compound and its application in lowering uric acid activity. Compounds 1-3 were isolated from the fermentation products of the endophytic fungus *Septoriella phragmitis*, with compound 1 being a novel compound. The fermentation products were purified using mixed solvent extraction, normal silica gel column chromatography, and high-performance liquid chromatography to obtain compounds 1-3. The inhibitory activity of compounds 1-3 on xanthine oxidase, a target related to gout symptoms, was tested. Experimental results showed that the novel compound 1 exhibited good inhibitory activity against xanthine oxidase. Molecular docking experiments also demonstrated that compound 1 had a good binding energy to the target protein. Therefore, compound 1 can be used to prepare a natural lead compound for delaying or treating diseases caused by xanthine oxidase, providing a potential therapeutic agent for hyperuricemia and gout.

The invention belongs to the field of gout prevention and treatment, and particularly relates to alpinia oxyphylla and turmeric tabletted sweets as well as a preparation method and application thereof. According to the alpinia oxyphylla and turmeric composition disclosed by the invention, alpinia oxyphylla and turmeric are taken as main components, the beautiful millettia root, the poria cocos, the kudzuvine root, the lithocarpus litseifolius, the purslane, the cassia seed, the black pepper and the dandelion are reasonably combined, and all the components are synergistically interacted, so that the prepared composition can remarkably improve the xanthine oxidase inhibition activity, can effectively relieve gout symptoms, and can be used for treating gout. The composition can be used for adjuvant therapy of gout patients. The tablet candy prepared by adding a sweetening agent into the alpinia oxyphylla turmeric composition disclosed by the invention is simple in preparation process, can be eaten for a long time as an auxiliary food in a gout treatment process, and has a great promoting effect on relieving gout symptoms.

The application discloses a tetrapeptide IR4 with uric acid reducing activity, and a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the tetrapeptide IR4 is IDWR, and the tetrapeptide IR4 can be prepared by a solid-phase synthesis method and an enzymatic hydrolysis method. The tetrapeptide IR4 is identified from a porphyra haitanensis protease hydrolysate, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 33.6% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with an anserine (which can reduce the uric acid content of zebrafish by 25.7%), the tetrapeptide IR4 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the tetrapeptide IR4 and the allopurinol has no significant difference. The tetrapeptide IR4 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The invention relates to the technical field of preparation of deep-sea longevity fish precise active peptides, in particular to a deep-sea longevity fish precise active peptide with uric acid reducing and anti-inflammatory effects as well as a preparation method and application of the deep-sea longevity fish precise active peptide. The preparation method comprises the following steps: carrying out medium-temperature pretreatment, carrying out step-by-step enzymolysis with alkaline protease and acid protease, centrifuging, filtering, carrying out ultrafiltration interception and the like, and screening out 10 non-reported non-toxic active peptide fragments. The active peptide has a multi-target synergistic effect, inhibits the activity of xanthine oxidase, regulates and controls the expression of uric acid resorption protein, regulates and controls the expression of uric acid transporter protein, realizes bidirectional regulation of uric acid metabolism, efficiently removes hydroxyl radicals, activates superoxide dismutase and reduces the content of inflammation-related factors. The technology is simple and easy to control, low in equipment requirement and suitable for large-scale production, the active ingredients are natural, safety is high, the active ingredients can serve as functional factors to be applied to functional food, health care products and the like, and safe and diversified intervention schemes are provided for hyperuricemia and related inflammation problems.

The invention belongs to the technical field of biological fermentation, and particularly relates to a preparation method and application of a fermented rhizoma smilacis glabrae extract. The invention relates to a fermented rhizoma smilacis glabrae extract, which is characterized in that a lactobacillus rhamnosus LR.M8 strain is utilized, the inhibition effect of the rhizoma smilacis glabrae extract on xanthine oxidase is improved through fermentation, and the treatment effect of the rhizoma smilacis glabrae extract on hyperuricemia is improved. The solution for improving the effect of the extract through biological fermentation is provided for solving the problems that the content of effective components in common medicinal and edible extracts is low, and the human body utilization rate is not high. The lactobacillus rhamnosus LR.M8 can effectively improve the adjusting effect of the rhizoma smilacis glabrae medicine and food homologous plant extract on uric acid balance, can reduce damage of inflammation to cells, and promotes in-vivo purine metabolism to recover balance. The fermentation method provided by the invention is simple and remarkable in effect, and has a wide application prospect.

An siRNA inhibiting xanthine oxidase (XO) gene expression, a pharmaceutical composition containing the siRNA, a siRNA conjugate, and an application of the siRNA in the preparation of drugs for treating and / or preventing uric acid metabolism disorder or diseases or physical conditions caused by uric acid metabolism disorder. Each nucleotide in the siRNA is an independent modified or unmodified nucleotide, and the siRNA contains a sense strand and an antisense strand.

The invention discloses a preparation method of 1, 7-dimethylxanthine, which adopts inosine as a starting material, and the developed catalyst porphyrin-loaded xanthine oxidase and nano metal oxide can be recycled for multiple times, thereby greatly lowering the production cost. More importantly, safety accidents occur frequently in recent years, a route design strategy for avoiding dangerous reactions becomes more and more important, and the route avoids the use of a diazotization dangerous process, so that the production safety risk is greatly reduced.

The invention belongs to the technical field of biological medicines and bioactive peptides, and relates to a xanthine oxidase inhibitory peptide derived from goat milk protein and application thereof. The amino acid sequence of the xanthine oxidase inhibitory peptide is as shown in SEQ ID NO. 1. The xanthine oxidase inhibitory peptide can be used for preparing a product for inhibiting xanthine oxidase or a product for regulating and controlling the uric acid level in a human body. The XOD regulation active peptide provided by the invention is safe in source and clear in structure, can be applied to the field of functional food or nutrition intervention, and provides a safe and natural active substance basis for diet regulation of hyperuricemia and related metabolic diseases.

The application discloses a pentapeptide IK5 with uric acid reducing activity as well as a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the pentapeptide IK5 is ITGYK, and the pentapeptide IK5 can be prepared by a solid-phase synthesis method and an enzymolysis method. The pentapeptide IK5 is identified from a protease enzymolysis liquid of a fine weak red winged seaweed, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 44.4% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with ananeine (which can reduce the uric acid content of zebrafish by 25.7%), the pentapeptide IK5 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the pentapeptide IK5 and the allopurinol has no significant difference. The pentapeptide IK5 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

The application discloses an aquatic antibacterial peptide with xanthine oxidase inhibiting function and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the antibacterial peptide is Arg (Ph)-Trp-Leu-Ala-Arg-Ile-Arg-Val-Ile-Arg-(D-Val)-Ala-Arg-NH2. The antibacterial peptide provided by the application has broad-spectrum and strong antibacterial activity. Meanwhile, in the process of constructing the antibacterial peptide for efficiently inhibiting aquatic pathogenic bacteria, it is first found that the peptide has good xanthine oxidase inhibiting activity. The antibacterial peptide has good stability, and the antibacterial activity retention rate is maintained at more than 85% within 240 h of treatment in the range of-20 DEG C to 37 DEG C.

The invention provides a method and equipment for screening xanthine oxidase inhibitory peptides. The method comprises the following steps: acquiring a first peptide fragment with xanthine oxidase inhibitory activity as a positive sample, and acquiring a second peptide fragment without activity as a negative sample; respectively carrying out activity labeling; performing quantization coding on the two peptide fragments by adopting amino acid physicochemical property descriptors to generate an initial feature matrix, and performing pooling operation on the matrix to obtain a fixed-length peptide fragment feature vector; training an ensemble learning classification model to obtain a xanthine oxidase inhibitory peptide prediction model by taking the fixed-length peptide fragment feature vector as input and the activity label as output; quantizing and coding the candidate peptide fragment set and then inputting the candidate peptide fragment set into the prediction model to obtain an inhibitory activity prediction probability; and screening out a xanthine oxidase inhibitory peptide candidate sequence with high confidence from the candidate peptide fragment set. Based on the method, the invention further provides screening equipment of the xanthine oxidase inhibitory peptide. According to the method, a large number of candidate peptide fragments can be quickly predicted, and a high-confidence candidate sequence is obtained.

The invention discloses a fermented chicory composition with xanthine oxidase inhibitory activity as well as a preparation method and application of the fermented chicory composition. The composition is prepared by taking chicory roots as a single plant raw material and fermenting the chicory roots with a composite flora consisting of lactobacillus plantarum, lactobacillus rhamnosus, bifidobacterium adolescentis and streptococcus thermophilus in a viable count ratio of 1: 1: 1: 1. The preparation method comprises the steps of culture medium preparation, inoculated fermentation and post-treatment. Through the synergistic fermentation effect of the specific flora and the chicory substrate, the xanthine oxidase inhibitory activity of the product is remarkably enhanced. Metabonomics analysis shows that various active ingredients such as phenolic acids and prebiotic oligosaccharides are remarkably enriched after fermentation, and a dual-action mechanism of directly inhibiting enzyme activity and indirectly regulating intestinal flora is formed. The composition is safe in raw materials and definite in effect, and can be used for preparing medicines, health-care foods or dietary supplements for prevention or adjuvant treatment of hyperuricemia, gout and related diseases.

The application belongs to the technical field of sensors and relates to an array sensor based on cerium-based metal organic framework nanoscale enzyme and detection application of perfluoroalkyl compounds. The array sensor is a Ce-MOF triple enzyme activity array sensor and has multiple independent sensing channels. The sensing channels contain Ce-MOF nanoscale enzyme and chromogenic substrate. The chromogenic substrate includes first, second and third chromogenic substrates. The first chromogenic substrate includes 3,3',5,5'-tetramethylbenzidine. The second chromogenic substrate includes 2,4-diamino phenol and 4-aminoantipyrine. The third chromogenic substrate includes xanthine, xanthine oxidase and nitrogen blue tetrazolium. The MOF nanoscale enzyme array sensor constructed by the application has high sensitivity and selectivity in the identification and differentiation of PFASs compounds. The array sensor can not only accurately distinguish single PFASs compounds but also quantitatively detect the compounds, and has good response to PFASs with different concentrations.

The present invention belongs to the field of medicine, and specifically relates to a phenyl ether compound containing a hexahydrofuro[3,2-b]furan structure and use thereof. The compound is a phenyl ether compound containing a hexahydrofuro[3,2-b]furan structure represented by general formula I or a pharmaceutically acceptable salt thereof, wherein substituents R1, R2, and R3 have the meanings given in the description. The compound disclosed in the present invention has significant inhibitory activity against xanthine oxidase, and the phenyl ether compound containing a hexahydrofuro[3,2-b]furan structure and the pharmaceutically acceptable salt thereof can be used for preparing a drug for treating hyperuricemia or gout.

The application discloses a pediococcus acidilactici, a bacterial agent, a microbial composition and application and products thereof for reducing uric acid, and belongs to the technical field of microorganisms. The application provides a pediococcus acidilactici with a preservation number of GDMCC No: 67942, and a 16S rDNA sequence of the pediococcus acidilactici is shown as SEQ ID NO. 1. The strain can degrade purine nucleosides, inhibit xanthine oxidase, and has strong antioxidant activity; can be efficiently fermented in a plantago major plant base to prepare a live / inactivated bacterial agent and a microbial composition. Animal experiments prove that the strain and the plantago major fermentation product can significantly reduce blood uric acid of a hyperuricemia model mouse, improve liver, kidney and intestinal injury, reduce inflammation, increase short-chain fatty acid level and regulate intestinal flora, and the inactivated fermentation product has better effect. The product can be prepared into food, health products or drugs, and is used for reducing uric acid and assisting in reducing uric acid, is safe and effective, and is suitable for long-term intervention.

The application discloses camel milk hypouricemic peptides with a hypouricemic effect and application thereof, and the amino acid sequence of the camel milk hypouricemic peptides is QPWMQ. The camel milk hypouricemic peptides can significantly inhibit the activity of xanthine oxidase (XOD) and / or adenosine deaminase (ADA), reduce the uric acid concentration in the body, maintain the normal level of uric acid in blood, and prevent and treat hyperuricemia; and the application fully excavates small-molecule bioactive substances of camel milk, and improves the nutritional value and economic value of camel milk.

This invention discloses a xanthine oxidase inhibitory peptide derived from Antarctic krill and its applications, belonging to the field of biotechnology, specifically relating to bioactive peptide technology. Using Antarctic krill protein as raw material, this invention obtains the xanthine oxidase inhibitory peptide WRIPSRL, with the amino acid sequence shown in SEQ ID NO: 1, through virtual screening, molecular docking, and in vitro activity verification techniques. This invention utilizes the BIOPEP-UWM platform for virtual hydrolysis, and obtains candidate peptides through PeptideRanker activity prediction and ToxinPred toxicity screening; then, molecular docking is performed with the xanthine oxidase crystal structure 1N5X using the Autodock Vina algorithm to screen for high-affinity peptides; in vitro activity assays show that the IC50 of the WRIPSRL peptide is high. 50 The value was 1.04 mM, and the inhibition rate reached 48.68% at a concentration of 1 mM.

The invention belongs to the technical field of coffee products, and particularly relates to a coffee composition for relieving depressive symptoms and a preparation method thereof. 25-30 parts of coffee beans, 6-10 parts of fructus rosae laevigatae, 6-10 parts of semen boitae, 8-12 parts of cortex albiziae and 1-3 parts of seaweed are limited, and different raw materials are extracted, decocted or subjected to enzymolysis, so that separation and retention of active ingredients of the raw materials are facilitated, and the active ingredients in fructus rosae laevigatae, semen boitae, cortex albiziae and seaweed have a protection effect on brain cells; the traditional Chinese medicine composition is beneficial to recovering the balance of a nervous system, relieving the inflammatory response in the brain, reducing the generation of oxygen free radicals, reducing the activity of xanthine oxidase in the cerebral cortex and improving the symptom of depression; and chlorogenic acid, nicotinic acid and the like in coffee can generate positive influence on depression symptoms. Therefore, the coffee composition provided by the invention can be used for relieving depression symptoms and provides a basis for adjuvant therapy of depression.

This invention discloses an abalone-derived xanthine oxidase inhibitory peptide and its application, belonging to the field of biopeptides. Using abalone as raw material, this invention employs a mild blanching-ultra-high pressure-ultrasound synergistic pretreatment process, followed by enzymatic hydrolysis, separation and purification, and bioinformatics screening combined with molecular docking technology to obtain four polypeptides with amino acid sequences as shown in SEQ ID NO. 1-4. Experimental results show that the abalone-derived polypeptides provided by this invention have outstanding XOD inhibitory activity, with a half-maximal inhibitory concentration as low as 0.53 mg / mL, superior to existing shellfish peptides. They are non-toxic or non-sensitizing and can effectively reduce uric acid and pro-inflammatory factor levels in a hyperuricemia cell model, and can be applied to the preparation of uric acid-lowering drugs. This invention effectively overcomes the shortcomings of low activity and limited sources of natural peptides, promotes the high-quality utilization of abalone protein resources, improves the level of deep processing in the abalone industry, and provides novel natural candidate substances and technical solutions for the prevention and treatment of hyperuricemia.

This invention discloses a *Xanthoceras sorbifolium* leaf extract, its preparation method, and its application. The preparation method includes the following steps: (1) drying the *Xanthoceras sorbifolium* leaves, pulverizing them, and sieving them; (2) hot-extracting the sieved *Xanthoceras sorbifolium* leaf powder with ethanol to obtain an ethanol extract of *Xanthoceras sorbifolium* leaves; (3) concentrating the ethanol extract of *Xanthoceras sorbifolium* leaves and freeze-drying it to obtain the *Xanthoceras sorbifolium* leaf extract. This invention uses a simple ethanol hot extraction method to obtain the *Xanthoceras sorbifolium* leaf extract. The *Xanthoceras sorbifolium* leaf extract obtained by this invention has significant inhibitory activity against xanthine oxidase.

The invention belongs to the technical field of traditional Chinese medicine modernization and medicine development, and particularly relates to a uric acid reducing product based on folium apocyni veneti extract and application of the uric acid reducing product. The core active component of the product is the folium apocyni veneti extract. In-vivo experiments prove that the extract can remarkably reduce the blood uric acid level and xanthine oxidase (XO) activity of a mouse with hyperuricemia. Six active ingredients entering blood are identified through in-vivo metabolism research. The direct interaction between the main active component and the target protein XO is verified from the molecular level through molecular docking, surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) technologies, and the uric acid reducing action mechanism of the compound is completely clarified. The invention provides a scientific basis and a high-quality product for developing a new uric acid-reducing drug effect of the folium apocyni veneti.

The application discloses astragalus peptides with xanthine oxidase inhibitory activity, a preparation method and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the astragalus peptides is EKWW. The application finds and proves that there is a polypeptide component with xanthine oxidase inhibitory activity in astragalus hydrolysate, wherein the astragalus peptides with the amino acid sequence of EKWW can effectively inhibit the activity of xanthine oxidase, have the effect of reducing the uric acid level, and can be used for preparing pharmaceutical preparations for relieving hyperuricemia.